Stock CARM CARISMA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Delayed Nasdaq
Other stock markets
 03:57:15 2024-06-10 pm EDT 		5-day change 1st Jan Change
1.29 USD +19.44% Intraday chart for Carisma Therapeutics, Inc. -0.12% -55.68%
May. 16 Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, A Novel HER2-Targeting CAR-Monocyte CI
May. 09 Carisma Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Carisma Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

83049e0b4698015e35f31ff46368c4.nbFC5Sq_qbPQ8p7RFUxw30E-Vhhwho9xO4rEWuL8Xzs.28k3oEbbnsfiv6qOcQEFkRMNPSAZ98EXD-uXb9qSCGjN1hK8bPLAnqS8yw~62ef0b78828a26a08e0d6de9d1bf5d4c

Analyst Recommendations on Carisma Therapeutics, Inc.

BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target MT
HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating MT
Capital Starts Carisma Therapeutics at Overweight With $10 Price Target MT
HC Wainwright Adjusts Price Target on CARISMA Therapeutics to $11 From $10, Keeps Buy Rating MT
Evercore ISI Initiates CARISMA Therapeutics at Outperform With $12 Price Target MT
HC Wainwright Starts Carisma Therapeutics at Buy With $10 Price Target MT
Baird Initiates CARISMA Therapeutics at Outperform With $10 Price Target MT
SESEN BIO : Jefferies & Co Downgrades Sesen Bio to Hold From Buy, Adjusts PT to $1.50 From $6 MT
SESEN BIO : Canaccord Genuity Adjusts Sesen Bio PT to $3 From $7, Maintains Buy Rating MT
SESEN BIO : HC Wainwright Downgrades Sesen Bio to Neutral From Buy MT
SESEN BIO : Jefferies Adjusts Price Target for Sesen Bio to $6 From $3, Maintains Buy Rating MT
SESEN BIO : Canaccord Adjusts Sesen Bio's Price Target to $7 from $5, Keeps Buy Rating MT
SESEN BIO : HC Wainwright Adjusts Sesen Bio's Price Target to Street-High $8 From $2.25, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.08 USD
Average target price
7.6 USD
Spread / Average Target
+603.70%
High Price Target
10 USD
Spread / Highest target
+825.93%
Low Price Target
4 USD
Spread / Lowest Target
+270.37%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Carisma Therapeutics, Inc.

BTIG
HC Wainwright
Capital One Securities
Evercore ISI
Baird
Canaccord Genuity
Jefferies & Co.

Ratings for Carisma Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CARM Stock
  4. Consensus Carisma Therapeutics, Inc.